Cargando…
Quantifying the persisting orphan-drug shortage public health crisis in the United States
Background: Orphan drugs (ODs) are pharmaceuticals manufactured for rare conditions that affect less than 200,000 people in the US. ODs are therefore produced in small quantities to meet sparse demand. Since 2010, OD shortages have become frequent, but no comprehensive, quantitative studies exist. O...
Autores principales: | Jarosławski, Szymon, Azaiez, Chiraz, Korchagina, Daria, Toumi, Mondher |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Routledge
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5560412/ https://www.ncbi.nlm.nih.gov/pubmed/28839523 http://dx.doi.org/10.1080/20016689.2017.1269473 |
Ejemplares similares
-
Patient-reported outcome claims in European and United States orphan drug approvals
por: Jarosławski, Szymon, et al.
Publicado: (2018) -
Low rates of patient-reported outcome claims for orphan drugs approved by the us food and drug administration
por: Jarosławski, Szymon, et al.
Publicado: (2018) -
Determinants of orphan drugs prices in France: a regression analysis
por: Korchagina, Daria, et al.
Publicado: (2017) -
Non-profit drug research and development: the case study of Genethon
por: Jarosławski, Szymon, et al.
Publicado: (2018) -
Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe
por: Medic, Goran, et al.
Publicado: (2017)